Beam Therapeutics Inc


Beam Therapeutics Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)32.37
  • Today's Change0.16 / 0.50%
  • Shares traded516.26k
  • 1 Year change-0.58%
  • Beta--
Data delayed at least 15 minutes, as of May 26 2023 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Beam Therapeutics Inc. is a biotechnology company engaged in providing life-long cures to patients suffering from serious diseases. The Company operates a fully integrated platform for precision genetic medicines. Its base editing technology enables a differentiated class of precision genetic medicines that target a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company is advancing its base editing technology across three disease-area portfolios: hematology, immunology/oncology and genetic diseases. Its clinical-stage programs include BEAM-101, BEAM-201, BEAM-301 and BEAM-302. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy designed to offer a profile, incorporating base edits that are intended to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin (HPFH). BEAM-201 is a development candidate comprised of T cells.

  • Revenue in USD (TTM)76.70m
  • Net income in USD-316.33m
  • Incorporated2017
  • Employees507.00
  • Location
    Beam Therapeutics Inc26 Landsdowne StCAMBRIDGE 02139-4216United StatesUSA
  • Phone+1 (857) 327-8775
  • Fax+1 (302) 655-5049
  • Websitehttps://beamtx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
BridgeBio Pharma Inc77.78m-424.94m2.21bn392.00------28.37-2.83-2.830.5215-7.640.1081----198,418.40-59.22-64.11-69.48-78.4596.4895.39-547.77-1,037.16----3.43--11.38--14.46--68.60--
Mirati Therapeutics Inc18.89m-737.07m2.24bn587.00--2.59--118.44-12.95-12.950.332214.830.0154--3.6332,187.39-60.04-45.22-66.80-49.4535.38---3,901.06-1,744.747.51--0.00---82.75---27.34--126.71--
Nuvalent Inc0.00-89.50m2.29bn70.00--5.14-----1.72-1.720.007.820.00----0.00-24.25---25.11--------------0.00-------76.65------
Corcept Therapeutics Incorporated413.82m94.50m2.44bn299.0029.444.9025.605.890.81450.81453.574.900.76210.961213.861,384,027.0017.4023.0819.9025.7598.6798.3922.8429.156.69--
Beam Therapeutics Inc76.70m-316.33m2.47bn507.00--3.16--32.17-4.46-4.461.0810.230.0551----151,274.20-20.88-35.05-24.78-42.04-----379.20-907.65----0.0032--17.51--22.00--169.24--
Akero Therapeutics Inc0.00-111.84m2.48bn41.00--6.86-----2.74-2.740.006.520.00----0.00-43.12-48.39-46.60-51.98-----------96.760.0744-------11.17------
Xenon Pharmaceuticals Inc668.00k-147.38m2.55bn203.00--3.68--3,814.69-2.24-2.240.010310.890.001--0.25973,290.64-23.07-21.60-23.64-23.05-----22,070.36-462.39----0.00---48.8397.87-62.07--55.83--
Revance Therapeutics Inc156.64m-351.87m2.56bn534.00------16.34-4.61-4.612.06-0.31750.26383.1215.79293,324.00-59.27-54.14-67.78-60.8761.73---224.65-531.623.79-23.901.07--70.40247.40-26.70--4.92--
Insmed Incorporated257.47m-546.68m2.56bn736.00------9.96-4.26-4.262.02-0.32730.19280.83819.16349,816.60-40.93-40.24-46.37-45.7677.9577.73-212.33-240.275.63-24.631.04--30.19---10.79--26.91--
Morphic Holding Inc68.95m-63.69m2.58bn102.00--5.32--37.36-1.63-1.631.7610.760.1644--54.18675,951.00-15.18-20.50-16.29-23.33-----92.38-171.12----0.00--257.72--38.20---17.33--
ProKidney Corp0.00-50.21m2.58bn87.00---------0.8159-0.81590.00-26.020.00----0.00-42.85------------------0.0004-------95.90------
Revolution Medicines Inc34.82m-259.16m2.72bn259.00--2.86--78.20-3.04-3.040.4068.960.0397--7.43141,528.50-29.52-30.02-31.53-33.44-----744.36-355.93----0.00--20.38---32.93--47.01--
Immunovant Inc0.00-210.96m2.75bn164.00--7.57-----1.71-1.710.002.780.00----0.00-45.79---50.62--------------0.00-------34.60------
Immunocore Holdings PLC - ADR204.65m-51.58m2.77bn408.00--8.19--13.55-1.10-,595.20-11.73---14.54--99.77---25.21--4.55--0.1991--441.99--68.66------
Azenta Inc594.21m-25.38m2.78bn3.70k--1.0378.064.68-0.343527.727.9941.580.23093.073.29185,691.30-0.98610.2068-1.110.241444.1642.99-4.270.5935.92--0.0005723.378.141.0460.91--43.07-24.21
Data as of May 26 2023. Currency figures normalised to Beam Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

52.48%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 31 Mar 20238.57m11.84%
The Vanguard Group, Inc.as of 31 Mar 20236.22m8.59%
BlackRock Fund Advisorsas of 31 Mar 20234.42m6.11%
Temasek Holdings Pte Ltd. (Investment Management)as of 31 Mar 20234.09m5.66%
Fidelity Management & Research Co. LLCas of 31 Mar 20233.95m5.46%
Farallon Capital Management LLCas of 31 Mar 20233.43m4.74%
SSgA Funds Management, Inc.as of 31 Mar 20233.24m4.47%
Redmile Group LLCas of 31 Mar 20231.61m2.23%
Deep Track Capital LPas of 31 Mar 20231.25m1.73%
Geode Capital Management LLCas of 31 Mar 20231.20m1.66%
More ▼
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.